Recombinant Mouse sTNF RII/TNFRSF1B Protein
R&D Systems, part of Bio-Techne | Catalog # 426-R2
Key Product Details
Product Specifications
Source
Val23-Gly258
Purity
Endotoxin Level
N-terminal Sequence Analysis
Predicted Molecular Mass
Activity
The ED50 for this effect is 1-3 µg/mL in the presence of 0.1 ng/mL of recombinant mouse TNF-alpha.
Formulation, Preparation and Storage
Carrier Free
What does CF mean?CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
Carrier: 426-R2
Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein. |
Reconstitution | Reconstitute at 10 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Carrier Free: 426-R2/CF
Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA. |
Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: TNF RII/TNFRSF1B
Tumor Necrosis Factor Receptor II (TNF RII), also known as TNFRSF1B, p75/p80, and CD120b, is a type I transmembrane protein that belongs to the TNF receptor superfamily. It has a molecular weight of approximately 75 kDa (1-4). The TNF receptor superfamily is comprised of structurally related receptors that bind to TNF-related ligands and regulate numerous processes such as immune cell activation and apoptosis. Receptors in this superfamily are characterized by the presence of a cysteine-rich region in their extracellular domain (ECD) (1-3, 5). Mouse TNF RII contains four cysteine-rich repeats in its ECD, which shares 58% and 84% amino acid sequence identity with the human and rat orthologs, respectively. Several receptors in the TNF superfamily also contain intracellular death domains (DDs) that recruit caspase-interacting proteins to initiate apoptosis upon ligand binding. Those receptors that lack DDs, like TNF RII, bind TNF Receptor-associated Factors, which transduce signals generated by activation of these receptors (6, 7).
TNF RII is expressed predominantly on cells of the hematopoietic lineage, such as T and natural killer cells, as well as on endothelial cells, microglia, astrocytes, neurons, oligodendrocytes, cardiac myocytes, and thymocytes (6, 8, 9). In humans, TNF RII is also located on mesenchymal stem cells (6, 9, 10). TNF RII binds to the membrane-bound forms of TNF-alpha and Lymphotoxin-alpha /TNF-beta ; soluble TNF is thought to signal predominately through TNF RI (7, 11). TNF RII activation primarily initiates pro-inflammatory and pro-survival responses via NF kappaB-dependent signaling pathways (6, 7, 12-15). However, under certain conditions, TNF RII signaling can induce apoptosis (6). TNF RII also exists as a soluble receptor, which can be generated by proteolytic cleavage of its ECD from the cell surface or by alternative splicing (2, 16). Soluble TNF RII is believed to inhibit TNF biological activity by binding TNF thereby preventing it from activating membrane TNF receptors (17). Polymorphisms of the human TNFR2 gene, which result in increased expression of both membrane-bound and soluble TNF RII, have been associated with several autoimmune diseases including Crohn’s disease, systemic lupus erythematosus, and familial rheumatoid arthritis (6, 17).
References
- Dembic, Z. et al. (1990) Cytokine 2:231.
- Kohno, T. et al. (1990) Proc. Natl. Acad. Sci. USA 87:8331.
- Lewis, M. et al. (1991) Proc. Natl. Acad. Sci. USA 88:2830.
- Loetscher, H. et al. (1990) J. Biol. Chem. 265:20131.
- Beltinger, C.P. et al. (1996) Genomics 35:94.
- Faustman, D. and M. Davis (2010) Nat. Rev. Drug Discov. 9:482.
- Ihnatko, R. and M. Kubeš (2007) Gen. Physiol. Biophys. 26:159.
- Mason, A.T. et al. (1995) J. Leukoc. Biol. 58:249.
- Speeckaert, M.M. et al. (2012) Am. J. Nephrol. 36:261.
- Böcker, W. et al. (2008) J. Mol. Med. 86:1183.
- Pennica, D. et al. (1992) J. Biol. Chem. 267:21172.
- Mak, T.W. and W.C. Yeh (2002) Arthritis Res. 4:S243.
- Aspalter, R.M. et al. (2003) J. Leukoc. Biol. 74:572.
- Bradley, J.R. (2008) J. Pathol. 214:149.
- McCoy, M.K. and M.G. Tansey (2008) J. Neuroinflammation 5:45.
- Lainez, B. et al. (2004) Int. Immunol. 16:169.
- Sennikov, S.V. et al. (2014) Mediators Inflamm. 2014:745909.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional TNF RII/TNFRSF1B Products
Product Documents for Recombinant Mouse sTNF RII/TNFRSF1B Protein
Product Specific Notices for Recombinant Mouse sTNF RII/TNFRSF1B Protein
For research use only